Looking for something specific? Drill down with our filter tools. Search with one or more of the options below.




  • Clear Selections

October 14, 2019  |  Podcast
Is It Science Fiction or Is It Healthcare?
[easy-social-share buttons=”twitter,linkedin,mail” counters=0 style=”icon” template=”33″ nospace=”no” fixedwidth=”yes” fixedwidth_px=”33″ point_type=”simple”]

Cell therapy, gene editing, and other medical technologies that focus on the human genome are more than science fiction. Find out how shifts in personalized medicine are transforming healthcare when we sit down with William Blair healthcare analysts Camilla Oxhamre Cruse, Ph.D., and Tommy Sternberg, CFA.

Camilla’s and Tommy’s comments are edited excerpts from our podcast, which you can listen to in full below. (39:46)


What are the big changes you’ve seen in healthcare over the past 15 years?

Tommy: The major themes in healthcare don’t change dramatically. At the end of the day, we want innovation to help people live longer, healthier lives, but how do we pay for it?

With that theme as context, I’ve seen three major changes in the pharmaceutical industry: pharmaceutical pricing; a change in business models; and an emphasis on personalized medicine.

The first, drug pricing, feels more and more center stage. Are prices too high?

Tommy: It’s a fascinating debate, and there are arguments on both sides. Clearly, we’ve reached a tipping point where affordability is an issue for the average American. This is largely a U.S. phenomenon, and what’s unique in the United States is that drug companies have the freedom to set drug prices.

But list prices are making headlines. Net pricing (what the drug companies collect) is a different story. The rate of increase has declined substantially. Early this decade, net pricing was rising by 9% per year. From 2013 to 2015, it declined to about 4%. And in 2018, net pricing was flat.

Why is this happening?

Tommy: There are two main reasons. First, with media and political scrutiny, more self-policing is occurring in the industry.

Second, there’s been consolidation in the supply chain. Pharmaceutical benefit managers (PBMs) have gained more buying power over the last several years. They’re negotiating prices and driving formulary decisions (deciding which drugs will get reimbursed and which ones won’t).

Will prices rise or fall as we try to cure more complex diseases?

Tommy: The manufacturing cost of a drug often is not very high relative to the overall price of the drug. But it takes hundreds of millions, if not billions, of dollars to develop a single new drug. But the hope is that with advances in our understanding, the industry will improve when it comes to identifying which drugs to develop. Then you will start to see that cost curve come down a bit.

Outsourcing allows bigger drug companies to focus on their core competencies, which is not the discovery of new drugs, but the selling and the marketing of drugs.

The second change you mentioned is a change in business models. What does that mean?

Tommy: Few new drugs that reach the market were discovered by the company that sells them. Only 6% of the industry’s pipeline today actually resides within the top 10 pharmaceutical companies. And pharmaceutical companies have decided to outsource other functions as well—running clinical trials, for example, and manufacturing services.

One reason is risk reduction—if something happens at your plant, you want a backup. Another reason is the rise of virtual biotech companies. If you’re a small biotech company with a promising drug in the pipeline but no sales, it can be very risky and expensive to build a new manufacturing plant, so you outsource the manufacturing function.

Outsourcing allows bigger drug companies to focus on their core competencies, which is not the discovery of new drugs, but the selling and the marketing of drugs.

The third big change you mentioned was personalized medicine. That sounds like an opportunity for pharmaceutical companies that are starved for growth, but what is it?

Camilla: Personalized medicine is tailoring medical treatment to our individual characteristics. The concept is nothing new; think about organ donations and blood transfusions, which need to be tailored to the recipient to avoid severe reactions.

But recently there’s been a shift in personalized medicine based on our understanding of the human genome. So now when we refer to personalized medicine, we mean our understanding of the person’s unique genetic profile and how that plays into the treatment of diseases.

How has our increased understanding of the genetic profile and the correlation to various diseases changed the pharmaceutical industry?

Camilla: Historically, the industry has focused on developing blockbuster drugs. While many of these drugs are helpful, their one-size-fits-all approach is not optimal for all diseases—particularly those where genetic background plays a significant role, such as various cancers.

Historically we’ve treated cancer patients pretty much the same way, using surgery, radiation, and chemotherapy.

But based on our understanding of the human genome, we can now select a treatment protocol based on the individual patient’s profile, with the aim of a more successful outcome, fewer side effects, and a better cost-benefit profile.

Can you provide an example?

Camilla: About 30% of breast cancer patients are HER2 positive, meaning their tumor over-expressed the protein HER2. Herceptin treatment targets HER2. Using Herceptin in HER2 patients has shown to significantly reduce the occurrence of the diseases compared to using traditional treatments.

I was at the medical conference where the breakthrough data on one of the first immuno-oncology drugs was presented, and there was euphoria. It’s truly revolutionary. We don’t often see medical history being written.

When talking about personalized medicine, we should probably mention developments we’ve seen in immuno-oncology.

Camilla: Absolutely. Immuno-oncology drugs take advantage of the body’s own immune system to fight cancer. This is a rather delicate business because overactivating the immune system can be lethal. But in recent years, there’s been tremendous development.

Last year, the scientists who detected the key mechanism behind immuno-oncology drugs received a Nobel Prize in medicine, which is unique, because it usually takes decades of research to achieve that.

I was at the medical conference where the breakthrough data on one of the first immuno-oncology drugs was presented, and there was euphoria. Doctors who have been treating cancer for 20 years with little development see the potential for a cure. It’s truly revolutionary. We don’t often see medical history being written.

You said we’re in the early stage of personalized medicine. What do we need to progress? Is it a matter of dollars, data, computing power?

Camilla: It will take time because there’s so much to do. We’re just scratching the surface. The further we dig, the more we learn. That’s why it’s so interesting being a healthcare analyst. It’s an extremely dynamic environment.

At the moment, there are three big technology trends that are making a huge impact on the industry: gene therapy, cell therapy, and gene editing.

What would be a good example of gene therapy?

Camilla: Gene therapy refers to any treatment that adds, removes, or changes a patient’s genetic material. There are a couple drugs on the market that do this.

One, approved just a few months ago, offers a potential cure for a truly horrible chronic neurological disease called spinal muscular atrophy (SMA), which affects babies. It does so at the jaw-dropping price of $2 million per patient, but it shows the potential of gene therapy.

Tommy: A specific gene was identified in infants with SMA, and there’s when gene therapy is relevant—where genes are missing or it’s not working properly. Other examples are sickle cell disease, muscular dystrophy, hemophilia, and some eye diseases.

What’s really exciting, as Camilla said, is these can be curative, one-time treatments because you’re not addressing the symptoms but the underlying cause of the disease.

How does cell therapy differ from gene therapy?

Camilla: Cell therapy involves transplantation of human cells. Bone marrow transplantation is an example, but we’ve recently seen the development of cell therapies focused on boosting the patient’s immune system.

One such immunotherapy approach that’s getting a lot of attention right now is CAR-T. Basically, doctors extract T-cells (the immune system’s infantry) from a patient, then modify and amplify them and reinstate them back into the patient.

There are currently two CAR-T treatments on the market that are approved for different types of blood cancer.

And gene editing?

Camilla: Gene editing is earlier in its development than gene therapy and cell therapy. There are no approved treatments today, but the development of a technology called CRISPR has recently accelerated development. CRISPR is used to edit genes. It’s basically a pair of molecular scissors. It cuts open a DNA strain, then edits a specific piece.

It’s a bit of science fiction, but there’s huge potential. The first patients are actually going into clinical trials for a specific cancer indication.

With gene editing, you change smaller pieces of the gene. If you have any ambition of creating your own Jurassic Park, this would be the technology you would use.

This is different from gene therapy, correct? It’s more preemptive?  

Camilla: They’re in the same bucket, but different. With gene editing, you change smaller pieces of the gene. If you have any ambition of creating your own Jurassic Park, this would be the technology you would use.

In fact, an American scientist claims he can bring back the mammoth using CRISPR technology. So while CRISPR comes with huge scientific potential, it also comes with a lot of ethical responsibility.

 If the pharmaceutical industry starts curing everyone rather than treating everyone, does that lead to a loss of revenues?

Tommy: You could go down that route, but I don’t think that we’ll start seeing it occur in mass in our lifetime. First, we have a long way to go in the development of these technologies.

At the same time, I don’t know that these technologies are all that different from other technologies that moved the needle. Drugs lose patent exclusivity after a certain number of years. New drugs come out and replace the older ones.

Camilla: And from a scientific perspective, this is really a dynamic setting. It’s constantly changing. For example, we’re now finding out the tumor cells are developing resistance to Herceptin. That will definitely keep us all busy for a very long time.

Tommy: Even if we live to 150, we’ll want to start living to 200. We’ll always find something to try to fix.

For more conversations on The Active Share, subscribe to the series on Apple Podcasts, Spotify, Google Podcasts, Stitcher, or TuneIn

[easy-social-share buttons=”twitter,linkedin,facebook,mail” counters=0 style=”icon” template=”33″ nospace=”no” fixedwidth=”yes” fixedwidth_px=”33″ point_type=”simple”]

Related Posts

Related Posts

Subscribe to Our Blog

Gain insights on macro market events, the economy, and investing strategies.
Receive our latest blog posts in your inbox.

Cookie Policy

At William Blair, your privacy is important and we want to be clear about the information we may collect when you visit our website. This policy explains how we use cookies and may be amended, from time to time, without notice. Please read the information below about our cookie use. By using this site you agree to the placement of cookies on your computer in accordance with the terms of this policy. If you would like to modify your browser to notify you when you receive a new cookie or to disable cookies, please refer to Managing Cookies below. Additional resources, and a link to our full Privacy and Security Policy may also be found below.

What are cookies? Cookies are text files containing small amounts of information that are downloaded to your device when you visit a website. When you revisit the website, the cookies allow the website to recognize your device and remember certain information about you. Cookies can serve many purposes (helping us to understand how visitors use the website, letting you navigate between pages efficiently, remembering your preferences, and generally improving your user experience). Cookies also can help ensure that we provide information to you that is relevant or that you have requested.

You also can learn more about cookies at

Our use of cookies

Session Cookies
Session cookies are used to temporarily store information about logged in users. These cookies do not collect information from the user’s computer, and do not identify the user. These cookies do not gather information about you that could be used for marketing purposes or remembering where you have been on the internet. The William Blair website uses the following session cookies:

  • “ASP.Net_SessionId”: this cookie helps to identify each browser session on the server so that the user has an uninterrupted journey through the William Blair Website. It expires automatically when the session ends.
  • “ARRAffinity”: these cookies are set by our hosting provider to help load pages efficiently by routing users to the same server consistently. They expire as soon as you close your browser.

Permanent Cookies
Permanent cookies are used to enhance a user’s browsing experience by “remembering” users on subsequent visits. Please note that if you delete these cookies, we will not be able to remember your preferences or your login details or provide you with the content you have requested. These cookies do not gather information about you that could be used for marketing purposes. If you no longer wish for us to remember your selections, you should delete cookies on your machine. The William Blair website uses the following permanent cookies:

  • “recentOffice” and “recentPeople” cookies to speed up navigation by giving you the option to return to pages you have already visited. The cookies expire one year after the last page was requested.
  • “SC_Analytics_Global_Cookie”: this persistent cookie identifies repeat visits from a single user. The cookie expires one year after the last page was requested.
  • “SC_Analytics_Session_Cookie”: this cookie is used to collect anonymised information about how visitors use the site, including the number of visitors, where visitors have come from before coming to the site and the pages they visit on the site. The cookie expires one year after the last page was requested.

Analytics Cookies
There are also certain unique cookies and/or third-party cookies that we may use for analytics purposes to enhance the performance of our website. These cookies may track and provide trend analysis on how our users interact with our website, or help us to track errors. The data collected will generally be aggregated to provide trends and usage patterns for business analysis, site/platform improvement and performance metrics. The type of information we collect includes how many visitors visit our website, when they visited, for how long and which areas of our website are visited and which services are used. While this analysis may be performed by third parties, only William Blair will review the analytics. Your use of our website indicates your consent to the use of these web analytics cookies. One of these third party analytic tools used is a web analytics service provided by Google. Google Analytics is one of the most widespread and trusted analytics solutions on the web for helping us to understand how you use the site and ways that we can improve your experience. Google Analytics uses cookies to help analyze how visitors use the William Blair & Company website. Four types of cookies are used by Google Analytics:

  • __utma Cookie A persistent cookie – remains on a computer, unless it expires or the cookie cache is cleared. It tracks visitors. Metrics associated with the Google __utma cookie include: first visit (unique visit), last visit (returning visit). This also includes Days and Visits to purchase calculations which afford ecommerce websites with data intelligence around purchasing sales funnels.
  • __utmb Cookie & __utmc Cookie These cookies work in tandem to calculate visit length. Google __utmb cookie demarks the exact arrival time, then Google __utmc registers the precise exit time of the user. Because __utmb counts entrance visits, it is a session cookie, and expires at the end of the session, e.g. when the user leaves the page. A timestamp of 30 minutes must pass before Google cookie __utmc expires. Given__utmc cannot tell if a browser or website session ends. Therefore, if no new page view is recorded in 30 minutes the cookie is expired.
  • __utmz Cookie Cookie __utmz monitors the HTTP Referrer and notes where a visitor arrived from, with the referrer siloed into type (Search engine (organic or cost per click), direct, social and unaccounted). From the HTTP Referrer the __utmz Cookie also registers, what keyword generated the visit plus geolocation data. This cookie lasts six months.
  • __utmv Cookie Google __utmv Cookie lasts “forever”. It is a persistent cookie. It is used for segmentation, data experimentation and the __utmv works hand in hand with the __utmz cookie to improve cookie targeting capabilities.

For further details on Google analytics cookies, visit cookies set by Google Analytics.

Targeting Cookies
William Blair may utilize a select set of cookies provided by third parties, such as Like and Share buttons. These cookies store non-personally identifiable information, but may store information that is available to third-party advertisers, publishers, or ad networks.

Managing Cookies
Most browsers are initially set to accept cookies. However, you have the ability to disable cookies if you wish, generally through changing your internet software browsing settings. It may also be possible to configure your browser settings to enable acceptance of specific cookies or to notify you each time a new cookie is about to be stored on your computer permitting you to decide whether to accept or reject the cookie. To manage your use of cookies, there are various resources available to you. For example the “Help” section on your browser may assist you. As our cookies allow you to access some of our website’s essential features, we recommend that you leave cookies enabled. Disabling cookies may mean that you experience reduced functionality or will be prevented from using our site altogether.

Additional Resources

William Blair & Company Privacy and Security Policy

Social Media Disclaimer

William Blair & Company, L.L.C. is a broker dealer and investment adviser dually registered with the U.S. Securities and Exchange Commission (“SEC”). William Blair, along with affiliated entities William Blair Investment Management, LLC and William Blair International, Ltd (collectively, “William Blair”) sponsors and publishes posts on or through pages, profiles, accounts, feeds, channels or other portions of various social media platforms, including but not limited to YouTube, Facebook, LinkedIn and Twitter (each, a “Site”) for educational, promotional or other business reasons.

About William Blair Posts

No William Blair post published on any social media platform is an offer to sell or a solicitation of an offer to buy shares of any William Blair investment product to any person in any jurisdiction in which an offer, solicitation, purchase or sale would be unlawful under the laws of such jurisdiction. Additionally, all William Blair posts published on any social media platform are for informational purposes only and should not be considered as investment advice or recommendations to invest in any particular security, strategy or investment product.

William Blair posts on social media may include statements concerning financial market trends, and are based on current market conditions, which will fluctuate and may be superseded by subsequent market events or for other reasons. Historic market trends are not reliable indicators of actual future market behavior or future performance of any particular investment which may differ materially, and should not be relied upon as such. The investment strategies and broad themes discussed in William Blair’s social media posts may be unsuitable for investors depending on their specific investment objectives and financial situation. Information contained in posts has been obtained from sources believed to be reliable, but not guaranteed. You should note that the materials on the social media platforms are provided “as is” without any express or implied warranties. Past performance is not a guarantee of future results. All investments involve a degree of risk, including the risk of loss. No part of William Blair posts may be altered without express written permission from William Blair.

William Blair posts may provide links to third party websites only as a convenience and the inclusion of such links does not imply any endorsement, approval, investigation, verification or monitoring by William Blair of any content or information contained within or accessible from the linked sites. While we make every attempt to provide links only to those websites we think are trustworthy and accurate, we cannot be responsible for the content or accuracy of the information presented on those websites and we specifically disclaim any liability for any loss or damages which you may incur, directly or indirectly, as a result of your use of them. We reserve the right to terminate a link to a third party website at any time.

General User Guidelines

Due to the highly regulated nature of our industry and as a matter of policy, William Blair, in some instances, may not reply to user comments. Please ensure that your contributions in relation to any William Blair posts are relevant and topical. Do not publish your own advertisements of any kind on any William Blair social media page or with respect to any William Blair posts. We ask you to be respectful and courteous and refrain from publishing, including through hyper-links, inappropriate or offensive material on any William Blair social media page. Do not attempt to promote investments (this includes posting testimonials, giving investment advice, or making recommendations about specific securities, securities strategies, products or services) on any William Blair social media page. Do not attempt to submit to William Blair any personal, confidential or account information through any William Blair social media page. William Blair is not subject to any obligations of confidentiality regarding information submitted to them through any William Blair social media page or otherwise through any social media platform.

Third-Party Posts on any William Blair Social Media Page

While William Blair may monitor third-party posts published on any William Blair social media page, such posts may be reviewed to ensure regulatory compliance, but otherwise are not edited before being displayed. Third-party posts on any William Blair social media page are the view and responsibility of the third-party, not William Blair. William Blair cannot guarantee the appropriateness, accuracy or usefulness of any third-party posts or of any third-party hyper-link, nor are they responsible for any unauthorized or copyrighted materials contributed by a third-party in any William Blair social media page. William Blair reserves the right to remove or edit any third-party posts or comments on any William Blair social media page that are inappropriate or that violate (or may violate) applicable regulations.

William Blair does not publish or otherwise disseminate statements relating to current or former clients’ positive experiences with or endorsements of William Blair and expects you to refrain from publishing such posts on any William Blair social media page. You should limit your posts on any William Blair social media page to investment themes rather than commenting, positively or negatively, on William Blair, its products, services or personnel. Although our clients may follow this account, this should not be interpreted as a testimonial regarding any client’s experience with our firm.

Any descriptions of, references to, or links to other products, publications or services do not constitute an endorsement, authorization, sponsorship by, or affiliation with William Blair with respect to any hyper-linked site or its sponsor, unless expressly stated by William Blair. William Blair expressly disclaims any responsibility for the posts, the accuracy of the information, and/or quality of products or services provided by or advertised on these third-party sites, as posted by third-parties on any William Blair Social media page.

Use Social Media Platforms at Your Own Risk

William Blair is in no way affiliated with any social media platform and has no responsibility for any social media page’s operations and services. William Blair and their respective affiliates, directors, officers, or employees are not liable for any direct, indirect, incidental, consequential, punitive or special damages arising out of or in any way connected with your access or use of, or inability to access or use, a social media platform, any William Blair social media page thereon or reliance on any William Blair post or any failure of performance, interruption, defect, delay in transmission, computer viruses or other harmful components, or line or system failure associated with a social media platform or any William Blair social media page thereon. Use of a social media platform or any William Blair social media page thereon is at your own risk.

Privacy Policy

William Blair is not responsible for the terms of use or privacy policies of any social media platform on which William Blair posts may appear, including in any William Blair social media page. For additional information regarding account security and privacy, refer to our Privacy and Security statement

Copyrights and Trademarks

Each social media page’s content and information, and all trademarks, service marks, trade names, trade dress, logos, copyrights and other intellectual property displayed on the Site by William Blair (“Content”) are protected by U.S. and worldwide copyright and trademark laws and treaty provisions, and are owned by, controlled by or licensed to William Blair or their respective owners. By using any social media page, we do not grant you any rights to reproduce, sell, or license any of the content contained herein, except that you may print a copy of the information contained herein for your personal use only. You may not reproduce or distribute the text or graphics to others or copy all or substantially all of the content to your own hard drive or server without the prior written permission of William Blair.

Permitted Uses of Our Sites and Content

We have listed below the permitted uses of our Content. We reserve the right to change our permitted uses at any time.

  • William Blair grants you a limited, revocable, nonexclusive and nontransferable right to view, store, bookmark, download, copy and print pages from the Site for your personal and noncommercial use only. Unless you receive our permission in advance, you may not exploit any of the Content commercially or forward it as a mass distribution.
  • If you link other websites to any Site, you may not imply or suggest that William Blair has endorsed or is affiliated with such websites and you may not display this Site as “framed” within another website.

Prohibited Uses of Our Sites and Content

William Blair does not grant, by implication, estoppel or otherwise, any license or right to use Content on any social media page other than those set forth above, and you shall not make any other use of such Content without William Blair’s written permission. Without limiting the generality of the foregoing:

  • You agree not to copy large portions of any social media page (such as by bots, robots or spiders that “harvest” the Site), interfere with the functioning of the Site or restrict or inhibit any others from using the Site.
  • If you download any pages from any social media page, you agree that you will not remove or obscure any copyright or other notices or legends contained in any such Content. You may not alter or modify the Content in your copies.
  • You may not (and may not encourage or assist others to) violate any law, regulation, rule or the intellectual property or contractual rights of others, or attempt to violate the security of any social media page or use or gain access to the identities, information or computers of others through any social media page.
  • You may not transmit any virus, worm, time bomb or similar system interference or corruptant through any social media page.

William Blair has the right (but not the obligation) to monitor any social media page for unauthorized or objectionable conduct and to take all appropriate actions in response, without notice to you. We reserve the right to change or supplement our website policies at any time to the fullest extent permitted by applicable law.

Forward-Looking Statements

Statements made on any social media page that look forward in time involve risks and uncertainties and are forward-looking statements. Such risks and uncertainties include, without limitation, the adverse effect from a decline in the securities markets or a decline in William Blair’s products’ performance, a general downturn in the economy, competition from other companies, changes in government policy or regulation, inability of William Blair to attract or retain key employees, unforeseen costs and other effects related to legal proceedings or investigations of governmental and self-regulatory organizations.

Forward-looking statements reflect our current views with respect to, among other things, the operations and performance of our businesses. You can identify these forward-looking statements by the use of words such as “outlook,” “believe,” “expect,” “potential,” “continue,” “may,” “should,” “seek,” “approximately,” “predict,” “intend,” “will,” “plan,” “estimate,” “anticipate” or the negative version of these words or other comparable words. Forward-looking statements are subject to various risks and uncertainties. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise.

International Use

The Content provided in or accessible through any social media page is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject William Blair to any registration or other requirement within such jurisdiction or country. William Blair reserves the right to limit access to the Site to any person, geographic region or jurisdiction. Unless otherwise expressly set forth herein, William Blair makes no representations that transactions, products or services discussed on or accessible through the Site are available or appropriate for sale or use in all jurisdictions or by all users, or that access by any user in the place it is located is not illegal or prohibited. Users who choose to access the Site from other locations do so on their own initiative and are responsible for establishing the legality, usability and correctness of any information or Content on the Site under the laws of any applicable jurisdictions. You may not use or export the Content on the Site or accessible through the Site in violation of applicable laws and regulations.

Transmission to and From any Social Media Page

Subject to any applicable terms and conditions set forth in our Privacy and Security Statement, any communication or other material that you send to us through the Internet or post on any social media page by electronic mail or otherwise, is and will be deemed to be non-confidential as between you and us and William Blair shall have no obligation of any kind with respect to such information. William Blair will be free to use, for any purpose, and without compensation due or payable to you, any ideas, concepts, know-how or techniques provided by you to William Blair through any social media page.

Disclaimer and Indemnity

William Blair and its affiliates disclaim, to the fullest extent permitted by law, all express and implied warranties of merchantability, fitness for a particular purpose, and non-infringement. If you live in a state that does not allow disclaimers of implied warranties, our disclaimer may not apply to you.

William Blair does not warrant that the information in any social media page is accurate, reliable or correct, that any social media page will be available at any particular time or location, or that any social media page is free of viruses or other harmful components. Electronic communications can be intercepted by third parties and, accordingly, electronic mail and other transmissions to and from any social media page or made via any social media page may not be secure.

The investments and strategies discussed in the content may not be suitable for all investors and are not obligations of William Blair or any of its affiliates or guaranteed by William Blair or any of its affiliates. The investments are not bank deposits and are not insured by the Federal Deposit Insurance Corporation or any other entity and are subject to investment risks, including the loss of the principal amount invested. Nothing contained on the Site constitutes investment, legal, tax or other advice nor is to be relied on in making an investment or other decision. You should obtain and carefully review any applicable prospectus, statement of additional information and/or offering memorandum as well the William Blair Form ADV, as applicable, before making any investment decision. Decisions based on information or materials contained on any social media page are the sole responsibility of the user.

As consideration for access to any social media page, you agree to indemnify and hold harmless William Blair and their employees, contractors, affiliates, officers and directors from and against any claims whatsoever and of any nature for damages, losses and causes of action, including but not limited to actions by third parties against you, William Blair or any of its Related Person, arising out of or in connection with any decisions that you make based on such Content, your use of any social media page, or your violation of our website policies. You agree to make William Blair, whole for any and all claims, losses, liabilities, and expenses (including attorneys’ fees) arising from your use of the Site or any violation of this the policies laid out in this Disclaimer, unless prohibited by law.

Miscellaneous Provisions

YouTube, Facebook, LinkedIn, Twitter, and any other social media sites are public sites. William Blair is in no way affiliated with them and has no responsibility for their operations and services or for related service sites. William Blair is not responsible for any social media platform’s terms of use or privacy or security policies, or any other third party sites that may be linked to by a social media platform. By using a social media platform, you accept at your own risk that the Internet and online communications medium may not perform as intended despite the efforts of William Blair, your Internet Service Provider, and you.

For additional information regarding account security and privacy, refer to our Privacy and Security statement. For customer service inquiries or questions about your accounts, please visit our website at:

Your Acceptance of these Terms

Your use of the Site constitutes your acceptance of the terms contained herein. You may reject these terms by leaving the Site at any time.

For additional information about William Blair or to contact us, please visit our website at:


The Bloomberg Barclays U.S. Aggregate Bond Index is a broad-based benchmark that measures the investment grade, U.S. dollar-denominated, fixed-rate taxable bond market, including Treasuries, government-related and corporate securities, mortgage-backed securities (agency fixed-rate and hybrid ARM pass-throughs), asset-backed securities, and commercial mortgage backed securities.

The MSCI ACWI IMI Index is a free float-adjusted, market capitalization-weighted index that captures large, mid, and small cap representation across developed and emerging markets.

The MSCI ACWI ex-US IMI Index is a free float-adjusted, market capitalization-weighted index that captures large, mid, and small cap representation across developed and emerging markets, excluding the U.S. The Value and Growth Indices are a subset of the Index that adopt a framework for style segmentation in which value and growth securities are characterized using different attributes. Multiple factors are used to identify value and growth characteristics.

The MSCI ACWI Small Cap Index is a free float-adjusted, market capitalization-weighted index that captures small cap representation across developed and emerging markets.

The MSCI Emerging Markets Index is a free float-adjusted, market capitalization-weighted index that is designed to measure the equity market performance of emerging markets.

The MSCI World Index is a free float-adjusted, market capitalization-weighted index that is designed to measure the equity market performance of developed markets.

The Russell 2000 Index is a market capitalization-weighted index designed to represent the small cap segment of the U.S. equity universe.

Index performance is for illustrative purposes only. The indices are unmanaged, do not incur fees or expenses, and cannot be invested in directly.

Alpha is a measure of an investment's return in excess of the market's return, after both have been adjusted for risk.

Beta is a measure of the volatility of an investment relative to the overall market, represented by a comparable benchmark.

Half-life is a statistical measure of the time required for the discrepancy between price and value to contract by half of its starting value. Fundamental value estimates are based on the Dynamic Allocation Strategies team's proprietary research.

P/E Ratio is a measure of valuation which compares share price to earnings per share, calculated using estimates for the next twelve months.

Standard deviation is a statistical measurement of variations from the average.

The William Blair Earnings Trend Model captures information about short- and medium-term changes in analyst estimates in an attempt to anticipate future estimate changes and stock performance. The score combines measurements of earnings revisions, momentum, and earnings surprise.

The William Blair Valuation Model combines varying metrics used to characterize the relationship between the stock’s trading price and its intrinsic value. By going beyond using only one or two measures, the model attempts to build a more holistic version of a stock’s worth vis-a-vis the market. The score combines measurements of earnings/cash flow based, asset-based, and model-based factors.